Effect of Pregabalin on Radiotherapy-Related Neuropathic Pain in Patients With Head and Neck Cancer: A Randomized Controlled Trial

Jingru Jiang, MD1; Yi Li, MD, PhD1; Qingyu Shen, MD, PhD1,2; Xiaoming Rong, MD, PhD1; Xiaolong Huang, MD1; Honghong Li, MD1; Lizhi Zhou, PhD3; Hai-Qiang Mai, MD, PhD4; Dong Zheng, MD, PhD5; Ming-Yuan Chen, MD, PhD4; Yongteng Xu, MD1; Jibin Li, PhD4; Xuan Hui, MD6; Charles B. Simone II, MD7; Jan Gaertner, MD8; Andreas A. Argyriou, MD, PhD9; Edward Chow, PhD10; Pingyan Chen3; and Yamei Tang, MD, PhD1

Pain is a common treatment-related adverse event (AE) among patients undergoing radiotherapy for head and neck cancers. Patients with head and neck cancer experience nociceptive and neuropathic pain after radiotherapy. Although various treatment strategies for radiotherapy-related, acute nociceptive pain have been widely investigated, chronic pain with a neuropathic component has rarely been studied, and thus its management remains an unmet clinical need.

Radiotherapy-related neuropathic pain is a late radiation injury with a high prevalence (31%) among cancer survivors in radiation oncology clinics.